Kristen Yen - Jan 4, 2024 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Officer title: Vice President, Clinical Operations
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Stock symbol
SLNO
Transactions as of
Jan 4, 2024
Transactions value $
$0
Form type
4
Date filed
1/8/2024, 05:37 PM
Previous filing
Dec 14, 2023
Next filing
Jan 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Award $0 +24K +1178.2% $0.00 26K Jan 4, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Employee stock option (right to buy) Award $0 +16K $0.00 16K Jan 4, 2024 Common Stock 16K $36.70 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 25% of RSUs shall vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
F2 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3 50% of the shares subject to the option shall vest on January 1, 2025 and one-twenty-fourth of the remaining shares subject to the option shall vest on each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Remarks:

Officer title: Vice President, Clinical Operations